Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

• Main Authors: Haruka Maeda (Author), Nobuo Saito (Author), Ataru Igarashi (Author), Masayuki Ishida (Author), Mayumi Terada (Author), Shingo Masuda (Author), Ryosuke Osawa (Author), Naoto Hosokawa (Author), Kei Nakashima (Author), Hiroshi Kamura (Author), Haruki Imura (Author), Hiroki Inoue (Author), Suguru Matsuzaka (Author), Yukihiro Sugimoto (Author), Osamu Kuwamitsu (Author), Iori Motohashi (Author), Toru Morikawa (Author), Rentaro Oda (Author), Yuiko Hoshina (Author), Takashi Matono (Author), Osamu Teshigahara (Author), Eiichiro Sando (Author), Sadaharu Asami (Author), Satoshi Kudo (Author), Noboru Akizuki (Author), Yoshikazu Muto (Author), Tomoichiro Hayakawa (Author), Tomoo Kishaba (Author), Yasuji Ohara (Author), Yoshinao Kubo (Author), Motoi Suzuki (Author), Konosuke Morimoto (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTBackground This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.Methods We conducted a test-negative case-control study. We included medically attended episodes...